The Application of the Design of Experiments and Artificial Neural Networks in the Development of a Fast and Straightforward HPLC-UV Method for Fluconazole Determination in Hemato-Oncologic Pediatric Patients and Its Adaptation to Therapeutic Drug Monitoring
Arkadiusz Adamiszak, Andrzej Czyrski, Bartosz Sznek, Edmund Grześkowiak, Agnieszka Bienert, Jinxiang Xi · 2024
Read The Application of the Design of Experiments and Artificial Neural Networks in the Development of a Fast and Straightforward HPLC-UV Method for Fluconazole Determination in Hemato-Oncologic Pediatric Patients and Its Adaptation to Therapeutic Drug Monitoring by Arkadiusz Adamiszak, Andrzej Czyrski, Bartosz Sznek, Edmund Grześkowiak, Agnieszka Bienert, Jinxiang Xi (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11679493.txt.
Description
Arkadiusz Adamiszak and co-authors build a fast lab method to measure an antifungal drug in children's blood, in a 2024 paper. Fluconazole treats grave fungal infections in children with blood cancers, and dosing must be watched closely. Too little fails the infection; too much harms the child.
Their method uses liquid chromatography with ultraviolet detection, tuned through planned experiments rather than trial and error. Two experiment designs and a small neural network each helped optimize the setup, from peak shape to sample recovery. The finished method covers a wide range of drug levels with a short run time. It was then adapted for routine drug monitoring in young patients, where blood volumes are small and speed matters.
Catalog record
| CREATOR | Arkadiusz Adamiszak, Andrzej Czyrski, Bartosz Sznek, Edmund Grześkowiak, Agnieszka Bienert, Jinxiang Xi |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |